Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$8.49
-0.23 (-2.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $35.3M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.8B
P/E
84.9x
↑EV/EBITDA
38.2x
↑ROE
3.7%
↑Gross Margin
39.4%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+21.7%
FCF CAGR
—
FCF margin
12.0%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $446.6M · net income $47.5M · FCF $53.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $446.6M | $446.6M | $511.6M | $299.9M | $247.6M |
| Net Income | $47.5M | $47.5M | $127.7M | $61.1M | $92.9M |
| EBITDA | $85.2M | $85.2M | $166.9M | $89.3M | $124.1M |
| EPS | 0.11 | 0.11 | 0.28 | 0.13 | 0.22 |
| Gross Margin | 39.4% | 39.4% | 51.6% | 55.9% | 71.2% |
| Operating Margin | 13.8% | 13.8% | 25.0% | 17.6% | 27.3% |
| Net Margin | 10.6% | 10.6% | 25.0% | 20.4% | 37.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 10.98 | 10.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $53.8M | $53.8M | $35.3M | $-26.0M | $-103.2M |
| Returns | |||||
| ROE | 3.7% | 3.7% | 10.0% | 5.0% | 7.9% |
| Valuation | |||||
| P/E | 84.90 | 84.90 | 34.29 | 82.08 | 75.14 |
| EV/EBITDA | 38.22 | 38.22 | 24.88 | 48.95 | 50.12 |
| P/B | 2.84 | 2.84 | 3.44 | 4.14 | 5.93 |
| Growth & Yield | |||||
| Revenue Growth | -12.7% | -12.7% | 70.6% | 21.1% | — |
| EPS Growth | -60.7% | -60.7% | 115.4% | -40.9% | — |
| Dividend Yield | 0.7% | 0.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
89.9%
EPS terminal req.
$0.75
Spread vs growth
-150.6%
5Y implied EPS CAGR
52.6%
EPS terminal req.
$0.91
Spread vs growth
-113.4%
10Y implied EPS CAGR
29.6%
EPS terminal req.
$1.47
Spread vs growth
-90.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.7%
Start / end P/E
35.0x → 77.2x
EPS bridge
0.28 → 0.11
Residual
-73.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.